Preventing Colon Cancer Together
Making Screenings More Patient Friendly
Though colonoscopies are the gold standard for colorectal cancer screening, there are a number of patient-friendly screening options that have become available for colon cancers.
There is a fecal-based, noninvasive DNA screening test for colorectal cancer available. This test couples sensitivity toward patient preference for less invasive options with the demand for more reliable screening methods. This multi-target stool DNA test combines testing the stool for molecular markers associated with colorectal cancers with a Fecal Immunochemical Test (FIT test) to look for blood in the stool that can be associated with colorectal polyps and cancers. This screening option is more sensitive for colorectal cancer detection than a FIT kit alone.
A FIT kit is an at-home test that screens for occult or hidden blood in the stool that could be a sign of precancerous polyps or colon cancer. A trained nurse navigator specialized in gastrointestinal (GI) cancers will follow up with participants of FIT kits regarding their results and serve as a guide to schedule additional testing and coordinate insurance needs. While the FIT should not replace colonoscopies, the test is a way of improving the community’s health awareness and ultimately getting those in need of healthcare scheduled for necessary appointments.
“Ideally, we would like everyone over the age of 45 to receive a colonoscopy and those with a family history of colon cancer to begin screenings even earlier. One out of three people in that age group has not been screened for colon cancer,” says Johanna Bendell, MD, Chief Development Officer, Director of the GI Cancer Research Program and Director of the Drug Development Program at Sarah Cannon. “With the FIT kits, there’s an 80 percent compliance rate, which increases early diagnosis. Patients can find out if they are at increased risk for colon cancer and should undergo additional testing.”
These are just two of a number of options available for patients. Other screening options include CT colonography (“virtual colonoscopy”), fecal occult blood tests (FOBT) and Given Imaging’s PillCam technology for colon cancer.
While some of these new screenings may be less effective than more invasive procedures and may lead to false positives, Dr. Bendell pointed out that these alternative methods are better than no screening at all, especially for patients who would otherwise forgo screening.
“It’s always better to get some information as opposed to none at all. We want to take whatever steps we can do to catch cancer when it’s in an operative, treatable stage,” she says. “This is especially true for colon cancer, which tends to mutate as it progresses, making it resistant to various treatments. If we can detect the polyps before they become abnormal, we can help to prevent the cancer altogether.”